Wu Haoran, Fang Xinyi, Jin De, Miao Runyu, Wei Jiahua, Zhao Tianyu, Dai Dan, Liao Jiangquan, Wang Jia, Lian Fengmei, Tian Jiaxing
Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Graduate College, Beijing University of Chinese Medicine, Beijing, China.
Front Pharmacol. 2022 Feb 4;13:827697. doi: 10.3389/fphar.2022.827697. eCollection 2022.
Type 2 diabetes mellitus (T2DM) complicated with dyslipidaemia is associated with a high risk of cardiovascular diseases. The Jiangtang Tiaozhi (JTTZ) recipe is a Chinese herbal formula that has been used to regulate the blood glucose and lipid levels for many years. Interestingly, a previous study has demonstrated its efficacy; however, the associated mechanism remains unclear. We hypothesised that the therapeutic effect of the JTTZ on patients with T2DM may be mediated by the modulation of metabolites secreted by the gut microbiota. This study aims to examine this mechanism. This study is a randomised, positive drug parallel-controlled, open-label clinical trial in patients with T2DM and dyslipidaemia. A total of 96 patients will be recruited and randomly assigned to treatment with JTTZ or metformin for 12 weeks. The primary outcome will be the rates of effectively regulated blood glucose and lipid levels (measured with the levels of glycated haemoglobin, fasting plasma glucose, 2-h plasma glucose, triglyceride, and low-density lipoprotein cholesterol). The secondary outcomes will be the changes in body weight, body mass index, and waist circumference and Traditional Chinese Medicine symptom scores. In addition, 16S rRNA gene sequencing will be performed on the gut microbiota obtained from faeces, and metabolomics analysis will be performed based on blood and gut microbiota samples. Intention-to-treat, per-protocol analysis and safety analysis will be performed. https://clinicaltrials.gov/ct2/show/NCT04623567.
2型糖尿病(T2DM)合并血脂异常与心血管疾病的高风险相关。降糖调脂(JTTZ)方剂是一种多年来一直用于调节血糖和血脂水平的中药配方。有趣的是,先前的一项研究已证明其疗效;然而,相关机制仍不清楚。我们假设JTTZ对T2DM患者的治疗作用可能是通过调节肠道微生物群分泌的代谢产物来介导的。本研究旨在探讨这一机制。本研究是一项针对T2DM合并血脂异常患者的随机、阳性药物平行对照、开放标签的临床试验。总共将招募96名患者,并随机分配接受JTTZ或二甲双胍治疗12周。主要结局将是血糖和血脂水平有效调节的比率(用糖化血红蛋白、空腹血糖、餐后2小时血糖、甘油三酯和低密度脂蛋白胆固醇水平衡量)。次要结局将是体重、体重指数、腰围和中医症状评分的变化。此外,将对从粪便中获得的肠道微生物群进行16S rRNA基因测序,并基于血液和肠道微生物群样本进行代谢组学分析。将进行意向性分析、符合方案分析和安全性分析。https://clinicaltrials.gov/ct2/show/NCT04623567